LYCERA CORPORATION
Patent Owner
Stats
- 21 US PATENTS IN FORCE
- 1 US APPLICATIONS PENDING
- Mar 20, 2018 most recent publication
Details
- 21 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 478 Total Citation Count
- Nov 08, 2011 Earliest Filing
- 1 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2015/0152,063 INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOFJun 07, 13Jun 04, 15[C07D]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9896441 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseMay 05, 15Feb 20, 18[C07D]
9809561 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of diseaseDec 19, 14Nov 07, 17[A61K, C07D]
9802958 Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of diseaseJul 08, 16Oct 31, 17[C07D]
9783511 Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of diseaseDec 19, 14Oct 10, 17[A61K, C07D]
9663502 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of diseaseDec 19, 14May 30, 17[A61K, C07D]
9657033 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of diseaseMay 07, 13May 23, 17[A61K, C07D]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0031,068 METHODS AND COMPOSITIONS FOR DETECTING IMMUNE SYSTEM ACTIVATIONAbandonedMar 15, 13Jan 29, 15[G01N]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.